Cereno Scientific Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Cereno Scientific today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s lead compound CS1, for the treatment of Pulmonary Arterial Hypertension (PAH). PAH is a form of high blood pressure in the lungs where the increased pressure is primarily caused by changes in the lung vessels.CS1 is a reformulation of valproic acid (VPA), an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties. These characteristics are a good match